carnegie-mellon
(3)
Myris Therapeutics
Myris Therapeutics is a Pittsburgh-based precision oncology company building the next generation of antibody drug conjugates (ADCs). Formerly BioHybrid Solutions, Myris uses proprietary polymer chemistry rooted in Carnegie Mellon's ATRP (atom transfer radical polymerization) technology to grow polymer bottlebrushes on antibodies, achieving ultra-high drug-to-antibody ratios (DAR) of 50-300 - roughly 10 to 100 times higher than conventional ADCs. That capability opens up new chemical space for cancer payloads that were previously unusable, aiming to deliver more potent, precisely targeted therapies.
Skild AI
Skild AI is a Pittsburgh-based robotics company building the Skild Brain, a single general-purpose foundation model designed to control any robot - quadrupeds, humanoids, tabletop arms, mobile manipulators - across many tasks without bespoke retraining. Founded in 2023 by former Carnegie Mellon professors Deepak Pathak and Abhinav Gupta, the company trains on a mix of large-scale simulation, internet video, teleoperation and real-world deployment data. After a $1.4B Series C in January 2026, Skild AI is valued at over $14 billion.
Stellic
Stellic is a centralized degree-progression platform used by universities to handle degree audits, academic advising, planning, registration, and analytics. Founded by Carnegie Mellon undergrads who hated the experience of mapping their own degrees, it now serves 80+ institutions and over a million students across the world.